Qiagen announced it has entered into a collaboration agreement with Eli Lilly and Company for the development and commercialization of companion diagnostics for pairing with Lilly investigational and approved medicines. Financial terms of the agreement are not being disclosed.
The agreement provides a framework for the two companies to collaborate on future projects – across all of Lilly’s therapeutic areas – aimed at bringing to market Lilly medicines paired with Qiagen diagnostics.
Qiagen says it is actively expanding its pipeline of tests for important biomarkers and intends to submit several companion diagnostics for U.S. regulatory approval. Last month, the company announced submission of its Therascreen EGFR RGQ PCR kit test to the FDA as a proposed companion diagnostic to guide treatment with a new investigational oncology compound developed by Boehringer Ingelheim. Qiagen is engaged in more than 15 projects with pharmaceutical and biotech companies to co-develop and market companion diagnostics.
Qiagen and Lilly have previously collaborated on companion diagnostics designed to run on Qiagen's Rotor-Gene Q system, a component of the QIAsymphony group of automated instruments. The company says its strategy is to develop FDA-approved diagnostics in the United States for use on this platform.